SpaceX IPO has been priced at 100X of Sales
Last quarter losses were over $ 4 Billion & Accumulated losses till date are $ 41 Billion. They are unlikely to make profits anytime soon.
Still got $ 250 Billion of bids Vs $ 75 Billion on offer. Amazing
Also on listing it will add another $1.75-2 Trillion to USA Market Capitalisation of $ 75 Trillion which is already 50% of World Market Capitalisation.
#ipo
#investment
- Mother: Invested in gold and forgot
- Father: Put money in FD and forgot
- Grand Father: Bought land and forgot
- This generation: Checking portfolio every 10 minutes hoping for recovery !!!
*Past*: Buy → Forget → Get rich
*Now*: Buy → Refresh → Repent → Repeat
This is current style of Gen Z
#stockmarket
#rajeshexport
Rajesh Exports allegedly overstated ₹15.15 lakh crore in revenue for FY21-FY25. If FY26 is added, the mismatch could rise by another ₹7.6 lakh crore. Total over 6 years: ~₹23 lakh crore. SEBI’s order covers only the last 5 years, so FY26 isn’t included. This could be the biggest accounting mismatch in Indian market history.
But the bigger question is: What were regulators like the Income Tax Dept, SEBI, and the statutory auditors doing for the last 5 years?
LIC holds ∼11% and FIIs hold ∼14%. So this again red flag for fund managers & its capability.
This may just be a Gross vs Net accounting treatment issue like GMV, but it needs a detailed investigation.
#stockmarket
#stock
#sharemarketindia
#sharemarket
Yesterday night horror show
Gold down 3.37%
Silver down 7%
Crude down 4%
Bitcoin down 5%
Nasdaq 100 down 3.1%: Major chip and storage stocks: Sandisk, WD, Micron, Intel down 7-8%
Korea market down 6%
Gift Nifty 1.5% down
Profit booking in AI stocks after jobs data.
Traders expecting a rate hike of 0.25% in US in 2026.
Lets see on Monday.
#rajeshexport
Rajesh Exports allegedly overstated ₹15.15 lakh crore in revenue for FY21-FY25. If FY26 is added, the mismatch could rise by another ₹7.6 lakh crore. Total over 6 years: ~₹23 lakh crore. SEBI’s order covers only the last 5 years, so FY26 isn’t included. This could be the biggest accounting mismatch in Indian market history.
But the bigger question is: What were regulators like the Income Tax Dept, SEBI, and the statutory auditors doing for the last 5 years?
LIC holds ∼11% and FIIs hold ∼14%. So this again red flag for fund managers & its capability.
This may just be a Gross vs Net accounting treatment issue like GMV, but it needs a detailed investigation.
#stockmarket
#stock
#sharemarketindia
#sharemarket
BULK DEAL ALERT:🚨
Sterlite Technologies Ltd
MOTILAL OSWAL MUTUAL FUND
Bought 36,48,537 shares @ Rs.619.07
At Multi year high 💵
Fund manager now realising Value of Diamond 💎?😄
Sterlite technologies is up 700% in just 4 months.
Identified even at INR 200
Bandhan MF has 5 % stake in Sterlite tech
Hdfc and Goldman sacs has more than 2 % each!
Other nearly 2 % is with Nippon and LIC!
Float is cornered in strong hands now💪💵🏌️
#Laurus Lab
Laurus Lab is looking good at CMP 665. Kindly eye on it. Going towards their all time high breakout level moving towards 800++. View negative below 610
Forget FIIs, Govt is also selling stake in PSUs one by one.
First Coal and now NHPC, 2nd OFS in last 7 days. Large OFS also loading in LIC too .
May be, to cover up Fiscal deficit problem.
..
STT Collections – Last 4 FYs
FY 2022-23: ₹25,085 Cr
FY 2023-24: ₹32,000 Cr
FY 2024-25: ₹53,296 Cr
FY 2025-26: ₹57,522 Cr
The data shows one thing clearly: the government earns consistently from capital market transactions regardless of whether investors profit or not.
When you add STT, STCG, LTCG, stamp duty, GST, and other levies on equity trades, the cumulative tax burden is making the Indian equity market less attractive for long-term capital.
With FIIs selling continuously, this additional tax drag will only add more pressure on the INR/USD exchange rate.
#stt
#ltcg
#stockmarket
#capitalmarket
#sharemarket
#indianeconomy
STT Collections – Last 4 FYs
FY 2022-23: ₹25,085 Cr
FY 2023-24: ₹32,000 Cr
FY 2024-25: ₹53,296 Cr
FY 2025-26: ₹57,522 Cr
The data shows one thing clearly: the government earns consistently from capital market transactions regardless of whether investors profit or not.
When you add STT, STCG, LTCG, stamp duty, GST, and other levies on equity trades, the cumulative tax burden is making the Indian equity market less attractive for long-term capital.
With FIIs selling continuously, this additional tax drag will only add more pressure on the INR/USD exchange rate.
#stt
#ltcg
#stockmarket
#capitalmarket
#sharemarket
#indianeconomy
April 1, 2018 (Reintroduction): The government reintroduced the tax at 10% on gains exceeding ₹1 lakh in a year. A "grandfathering" clause protected all gains accrued up to January 31, 2018.
The Union Budget 2024 raised the LTCG tax rate from 10% to 12.5%, while increasing the tax-free limit to ₹1.25 lakhs
FIIS Selling continues:
Year 2024: 1.19 lacs Crs
Year 2025: 1.66 lacs Crs
Year 2026: 2.26 lacs Crs
This clearly shows hows Indian market less attractive in last few years as compared to other emerging market like Taiwan, Kospi, Hongkong etc.
This also more pressurized to INR due to high selling by FIIS and USD repatriate.
'Abolish LTCG'
Vijay Kedia Wants LTCG Tax To Be Abolished: 'India Needs More Patient Capital, Entrepreneurship'
Read: https://t.co/SeT9eDcYWP
Make in India ✅
Stay invested in India ✅
Get taxed for staying ✅✅✅
12.5% LTCG: When govt loves your gains more than you do.
#ReduceLTCG #CompoundingKiller
@VijayKedia1
I don’t understand the rationale for not reducing the LTCG tax on equity.
FIIs have been net sellers continuously, and increasing the LTCG tax on equity so far hasn’t achieved the intended outcome. If long-term profits are made, the government will collect taxes anyway. If investors aren’t making profits, what is the benefit of retaining the LTCG tax?
The same applies to STCG. The rising trend over the past several years has made the Indian equity market less attractive to FIIs compared to other emerging markets.
Despite multiple policy measures, this issue hasn’t been addressed, which is surprising.
#indianeconomy
#StockMarket
#StockPortfolio
#stockmarkets
#sharemarket
India to attract Rs 1,90,000 Crore investment in Data Centre by 2030 🔥
India’s data centre capacity to 3X by 2030, expected to grow 26% CAGR for 5 years 🔥
Many Multibaggers will be made in this theme 👇🏻
1) IT Hardware / AI Servers 🤖
Opportunity : 66,500–85,500 Cr
• Netweb Tech
• Syrma SGS
• HFCL
2) Power Infrastructure ⚡
Opportunity : 38,000–47,500 Cr
• Hitachi Energy
• Siemens India
• ABB
• CG Power
• Cummins India
• Kirloskar Oil Engines
• Schneider Electric
3) Cooling Systems 🌬️
Opportunity : 28,500–38,000 Cr
• KRN Heat Exchangers
• Amber Enterprises India
• Thermax
• Kirloskar Brothers
4) Building & Civil 🏗️
Opportunity : 19,000–28,500 Cr
• KEC International
• Kalpataru Projects International
• Capacite Infraprojects
• PSP Projects
• Man Infra
5) Wires & Cables 🚡
Opportunity : 7,500–11,500 Cr
• Polycab India
• KEI Industries
• RR Kabel
• Universal Cables
• Sterlite Technologies
Rising AI adoption could drive deployment of 650,000 - 700,000 GPUs in India's data centres over the next 5 years: Avendus Capital, an Investment bank
Disclaimer: This is not buy/sell recommendations. Do your own DD before buy/sell the shares.
#ErisLife
Eris Life Science
📊 FY26 Financial Snapshot
Net profit surged 76% YoY to ₹619.52 crore for FY26, while sales grew 8.18% to ₹3,114.89 crore. More impressive was Q4 FY26 where net profit shot up 200% to ₹281.61 crore versus ₹93.84 crore in Q4 FY25 — a significant one-quarter jump largely driven by tax/one-time benefits
On the domestic branded formulations (DBF) front — the core business — Q4 revenue was ₹671 crore and full-year DBF revenue hit ₹2,778 crore, with EBITDA margin expanding from 36.5% to 37% in FY26.
🔑 Key Business Themes
Insulin — Dominant market share gains: Market share in RHI cartridges jumped from 13% to 24% during the year. Overall insulin segment share (RHI + glargine) rose from 12% to 16%, with insulin growth outpacing the covered market by nearly 5x.
Semaglutide (GLP-1/Obesity) — Big new bet: Eris launched its semaglutide brand "Sunde" — vials in March, 2mg pen in mid-April, 4mg pen in early May. Despite a phased launch, the pen achieved 11% volume share and 6% value share in the segment. Over 75% of prescriptions are currently diabetes-driven rather than obesity, and the active user base was estimated at 1.5–2 lakh in April alone
Acquisitions: A ₹50 crore probiotic business (Velbiom) acquisition was completed, and a ₹7.21/share interim dividend was declared with record date May 29, 2026.
📈 Future Forecast (FY27 Guidance)
Management has guided for 18–20% revenue growth in FY27 — one of the stronger guidance numbers in the Indian pharma space.
International business is expected to be a breakout year in FY27, with projected revenue of ₹550–600 crore and EBITDA of ₹180–200 crore.
The company expects 30% growth over covered market growth in the current year, with a robust pipeline including an obesity SKU and further insulin expansion.
Best ad campaign of the year - done accidentally by two Prime Ministers and one ₹1 Melody toffee. - Parle ki to Balle Balle now 😉😃
Melody khao Khud Jaan Jao.
#parle